Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
A topical pharmaceutical combination of hyaluronic acid and silver sulfadiazine used primarily for the treatment and prevention of wound infections in burns and chronic wounds. Hyaluronic acid is a naturally occurring glycosaminoglycan that promotes tissue repair by supporting cell migration, proliferation, granulation tissue formation, and modulating inflammation. Silver sulfadiazine is a sulfonamide antibiotic with broad-spectrum antimicrobial activity against gram-positive bacteria, gram-negative bacteria, and some fungi; it acts by releasing silver ions that disrupt microbial cell walls and DNA. The combination leverages the regenerative properties of hyaluronic acid with the antimicrobial effects of silver sulfadiazine to accelerate healing while reducing infection risk. This fixed-dose product is indicated for second-degree burns, chronic ulcers (including diabetic ulcers), post-traumatic wounds, superficial abrasions, parastomal ulcerations, and other complicated skin lesions at risk of infection[1][2][4][8].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on hyaluronic acid + silver sulfadiazine.